Meningitis, Meningococcal, Serogroup B

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Meningitis, Meningococcal, Serogroup B trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT06832514

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

Sexual differences are a well-established source of biological variation in immune system functioning, with men often displaying lower adaptive immune responses…

Belgium250 participantsStarted 2025-01-31

Treatment: Serogroup B meningococal vaccine

All recent trials (22 shown)

CompletedPhase 4

NCT01593514

Understanding the Immune Response to Two Different Meningitis Vaccines

The bacterium (germ) Neisseria meningitidis causes meningitis and blood poisoning. N meningitidis is classified into different serogroups (types), based on its…

United Kingdom20 participantsStarted 2012-12

Treatment: MenACWY-CRM conjugate vaccine (Menveo, Novartis), MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)

Active — Not RecruitingPhase 4

NCT06113198

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants…

The purpose of this study is to assess the safety and immune responses of rMenB+OMV NZ vaccine when administered to healthy infants from 2 months in the Republi…

South Korea50 participantsStarted 2023-11-10

Treatment:

Meningitis, Meningococcal, Serogroup B

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

All recent trials (22 shown)

Understanding the Immune Response to Two Different Meningitis Vaccines

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants…

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

All recent trials (22 shown)

Understanding the Immune Response to Two Different Meningitis Vaccines

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants…

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Heal…

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningoc…

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When…

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To…

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When G…

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Investigating the Immune Response to 4CMenB in Infants

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With…

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Ag…

Safety Surveillance of MenACWY-CRM Vaccine in Children

Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1…

Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pert…

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Safety of MenACWY-CRM Vaccination in Adolescents